Trial Profile
A randomized, phase III trial of sequential capecitabine/5FU plus bevacizumab (Cape/5FU-Bmab) to capecitabine/5FU plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms C Cubed; C3
- 22 Jan 2022 Results (n=292) of quality of life (QOL) analysis, presented at the 2022 Gastrointestinal Cancers Symposium
- 22 Feb 2019 Status changed from active, no longer recruiting to completed.
- 11 Oct 2016 Status changed from recruiting to active, no longer recruiting.